$IPSC (CENTURY THERAPEUTICS) — 8-K: Century Therapeutics appoints Joseph Truitt to board as CNTY-813 IND stays on track for Q4 2026

Century Therapeutics added Joseph Truitt, CEO of iECURE, to its Board of Directors. Truitt previously led BioSpecifics Technologies and Achillion Pharmaceuticals through acquisitions. The appointment comes as CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, remains on track for an IND submission in the fourth quarter of 2026 following a pre-IND meeting with the FDA. CNTY-308, a CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases, is anticipated to enter the clinic in 2026.

Century Therapeutics added Joseph Truitt, CEO of iECURE, to its Board of Directors. Truitt previously led BioSpecifics Technologies and Achillion Pharmaceuticals through acquisitions. The appointment